Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(1)

Detailed Status

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed267%

unknown133%

Recent Activity

0 active trials

Showing 3 of 3

unknownphase_1

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

NCT01843686

completedphase_1

Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma

NCT01837264

completedphase_1

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

NCT01386216

Clinical Trials (3)

Showing 3 of 3 trials

NCT01843686Phase 1

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

Unknown

NCT01837264Phase 1

Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma

Completed

NCT01386216Phase 1

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

Completed

All 3 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 3